| Literature DB >> 34632043 |
Tomoya Okazaki1, Takuo Yoshida2,3, Shigehiko Uchino2, Yusuke Sasabuchi4.
Abstract
BACKGROUND: New-onset atrial fibrillation (AF) in critically ill patients is associated with adverse outcomes. In non-critical settings, the circadian variation in paroxysmal AF is of significant interest; however, circadian variation in critically ill patients with new-onset AF has not been thoroughly studied. This study aimed to examine the association between AF onset time and in-hospital mortality.Entities:
Keywords: Critical illness; In-hospital mortality; New-onset atrial fibrillation; Onset time
Year: 2021 PMID: 34632043 PMCID: PMC8488237 DOI: 10.1016/j.ijcha.2021.100880
Source DB: PubMed Journal: Int J Cardiol Heart Vasc ISSN: 2352-9067
Baseline characteristics: AF onset during evening and nighttime vs. daytime.
| Variables | Total | Nighttime | Daytime | Evening | Missing data | ||
|---|---|---|---|---|---|---|---|
| ICU admission time | 0.614 | 0 | |||||
| Nighttime, n (%) | 82 (19) | 29 (22) | 28 (20) | 25 (17) | |||
| Daytime, n (%) | 151 (36) | 47 (35) | 55 (39) | 49 (33) | |||
| Evening, n (%) | 190 (45) | 59 (44) | 58 (41) | 73 (45) | |||
| Age, years | 75 [67, 81] | 75 [68, 82] | 74 [65, 81] | 75 [67, 81] | 0.455 | 0 | |
| Male sex, n (%) | 286 (68) | 94 (70) | 95 (67) | 97 (66) | 0.806 | 0 | |
| Body mass index, kg/m2 | 22.5 | 22.9 | 22.6 | 22.0 | 0.312 | 1 | |
| APACHE II score | 23 [18, 29] | 23 [18, 29] | 23 [19, 27] | 24 [17, 32] | 0.621 | 0 | |
| Patient category | 0.542 | 0 | |||||
| Non-scheduled surgery, n (%) | 95 (23) | 28 (21) | 28 (20) | 39 (27) | |||
| Scheduled surgery, n (%) | 61 (14) | 23 (17) | 19 (14) | 19 (13) | |||
| Medical, n (%) | 267 (63) | 84 (62) | 94 (67) | 89 (61) | |||
| Disease category | 0.334 | 0 | |||||
| Cardiovascular disorder | 55 (13) | 21 (16) | 17 (12) | 17 (12) | |||
| Respiratory disorder | 110 (26) | 31 (23) | 40 (28) | 39 (27) | |||
| Gastrointestinal disorder | 118 (28) | 41 (30) | 31 (22) | 46 (31) | |||
| Neurologic disorder | 24 (5.7) | 5 (3.7) | 12 (8.5) | 7 (4.8) | |||
| Trauma | 26 (6.1) | 8 (5.9) | 9 (6.4) | 9 (6.1) | |||
| Metabolic disorder | 13 (3.1) | 2 (1.5) | 5 (3.5) | 6 (4.1) | |||
| Hematologic disorder | 9 (2.1) | 3 (2.2) | 5 (3.5) | 1 (0.7) | |||
| Urogenital disorder | 21 (5.0) | 5 (3.7) | 6 (4.3) | 10 (6.8) | |||
| Musculoskeletal or skin disorder | 20 (4.7) | 5 (3.7) | 9 (6.4) | 6 (4.1) | |||
| Others | 27 (6.4) | 14 (10) | 7 (5.0) | 6 (4.1) | |||
| Pre-existing condition | |||||||
| Ischemic heart disease, n (%) | 43 (10) | 12 (8.9) | 13 (9.2) | 18 (12) | 0.584 | 0 | |
| Congestive heart failure, n (%) | 43 (10) | 15 (11) | 9 (6.4) | 19 (13) | 0.168 | 0 | |
| Hypertension, n (%) | 199 (47) | 63 (47) | 60 (43) | 76 (52) | 0.297 | 0 | |
| Diabetes mellitus, n (%) | 112 (27) | 34 (25) | 36 (26) | 42 (29) | 0.774 | 0 | |
| Stroke or TIA, n (%) | 45 (11) | 17 (13) | 15 (11) | 13 (8.8) | 0.594 | 0 | |
| Chronic hemolysis, n (%) | 24 (5.7) | 6 (4.4) | 8 (5.7) | 10 (6.8) | 0.694 | 0 | |
| Previous medication | |||||||
| Calcium-channel blockers, n (%) | 141 (33) | 42 (31) | 40 (28) | 59 (40) | 0.085 | 0 | |
| β-Blocking agents, n (%) | 56 (13) | 25 (19) | 10 (7.1) | 21 (14) | 0.018 | 0 | |
| ACE inhibitors, n (%) | 22 (5.2) | 6 (4.4) | 7 (5.0) | 9 (6.1) | 0.808 | 0 | |
| ARBs, n (%) | 89 (21) | 25 (19) | 31 (22) | 33 (22) | 0.681 | 0 | |
| Antidiabetic agents, n (%) | 97 (23) | 29 (22) | 32 (23) | 36 (25) | 0.832 | 0 | |
| Antiarrhythmic drugs, n (%) | 5 (1.2) | 2 (1.5) | 2 (1.4) | 1 (0.7) | 0.784 | 0 | |
AF atrial fibrillation, ICU intensive care unit, APACHE II Acute Physiology and Chronic Health Evaluation II, TIA transient ischemic attack, ACE angiotensin converting enzyme, ARBs angiotensin II receptor blockers
Kruskal-Wallis tests for continuous variables, and chi-square tests or Fisher’s exact tests for categorical variables between the three groups
p < 0.05 vs. nighttime group after Bonferroni correction
Patient conditions and laboratory data: AF onset during evening and nighttime vs. daytime.
| Variables | Total | Nighttime | Daytime | Evening | Missing data | |||
|---|---|---|---|---|---|---|---|---|
| From ICU admission to AF onset, days | 1.6 [0.7, 3.0] | 1.5 [0.6, 3.2] | 1.7 [0.8, 4.0] | 1.4 [0.4, 2.9] | 0.130 | 0 | ||
| Heart rate before AF onset, beats per min | 95 [83, 107] | 92 [82, 103] | 97 [86, 109] | 96 [82, 107] | 0.180 | 0 | ||
| MAP before AF onset, mmHg | 80 [71, 92] | 80 [69, 89] | 79 [70, 91] | 84 [73, 94] | 0.120 | 0 | ||
| Heart rate after AF onset, beats per min | 130 [112, 148] | 128 [111, 146] | 133 [115, 150] | 131 [109, 148] | 0.413 | 0 | ||
| MAP after AF onset, mmHg | 76 [64, 89] | 77 [63, 87] | 74.00 [63, 89] | 79 [67, 93] | 0.090 | 0 | ||
| Glasgow Coma Scale after AF onset | 14 [12, 15] | 14 [12, 15] | 14 [12, 15] | 15 [12, 15] | 0.744 | 0 | ||
| Antiarrhythmic drug at AF onset, n (%) | 40 (10) | 14 (10) | 14 (10) | 12 (8) | 0.796 | 0 | ||
| Vasopressors at AF onset, n (%) | 192 (45) | 59 (44) | 72 (51) | 61 (42) | 0.236 | 0 | ||
| Noradrenaline, n (%) | 182 (43) | 56 (41) | 68 (48) | 58 (39) | 0.293 | 0 | ||
| Noradrenaline, μg/kg/min | 0.12 | 0.10 | 0.15 | 0.15 | 0.405 | 0 | ||
| Adrenaline, n (%) | 14 (3) | 5 (4) | 4 (3) | 5 (3) | 0.944 | 0 | ||
| Adrenaline, μg/kg/min | 0.05 | 0.07 | 0.10 | 0.05 | 0.960 | 0 | ||
| Dopamine, n (%) | 32 (8) | 7 (5) | 11 (8) | 14 (10) | 0.385 | 0 | ||
| Dopamine, μg/kg/min | 3.4 [2.1, 4.9] | 3.0 [2.4, 5.3] | 2.6 [1.5, 4.0] | 3.8 [3.0, 4.8] | 0.401 | 0 | ||
| Vasopressin, n (%) | 39 (9) | 11 (8) | 12 (9) | 16 (11) | 0.685 | 0 | ||
| Inotropes at AF onset, n (%) | 52 (12) | 20 (15) | 20 (14) | 12 (8) | 0.166 | 0 | ||
| Dobutamine, n (%) | 41 (10) | 17 (13) | 16 (11) | 8 (5) | 0.092 | 0 | ||
| PDE inhibitors, n (%) | 12 (3) | 4 (3) | 4 (3) | 4 (3) | 1.000 | 0 | ||
| Sedative drug at AF onset, n (%) | 181 (43) | 67 (50) | 49 (35) | 65 (44) | 0.040 | 0 | ||
| Midazolam at AF onset, n (%) | 47 (11) | 16 (12) | 13 (9) | 18 (12) | 0.678 | 0 | ||
| Propofol at AF onset, n (%) | 87 (21) | 32 (24) | 24 (17) | 31 (21) | 0.382 | 0 | ||
| Dexmedetomidine, n (%) | 84 (20) | 31 (23) | 24 (17) | 29 (20) | 0.465 | 0 | ||
| MV at AF onset, n (%) | 255 (60) | 81 (60) | 81 (57) | 93 (63) | 0.599 | 0 | ||
| RRT at AF onset, n (%) | 104 (25) | 29 (22) | 33 (23) | 42 (29) | 0.356 | 0 | ||
| SOFA score at AF onset | 7 [5, 10] | 7 [5, 10] | 8 [5, 10] | 7 [4, 10] | 0.662 | 11 | ||
| Infection at AF onset, n (%) | 295 (70) | 92 (68) | 105 (75) | 98 (67) | 0.314 | 0 | ||
| Sepsis at AF onset | 286 (69) | 90 (67) | 100 (74) | 96 (68) | 0.354 | 11 | ||
| Septic shock at AF onset | 76 (18) | 18 (13) | 34 (25) | 24 (17) | 0.036 | 11 | ||
| Lactate, mmol/L | 1.6 [1.1, 2.4] | 1.5 [1.1, 2.1] | 1.7 [1.1, 2.6] | 1.6 [1.2, 2.4] | 0.325 | 5 | ||
| White blood cells, 103/μL | 10 [7, 15] | 10 [7, 14] | 10 [6, 15] | 11 [7, 16] | 0.515 | 3 | ||
| C-reactive protein, mg/dL | 13.1 [5.0, 23.6] | 10.8 [4.3, 20.2] | 18.4 [7.1, 26.5] | 12.4 [3.5, 22.7] | 0.001 | 11 | ||
| Sodium concentration, mmol/L | 140 [137, 143] | 140 [137, 143] | 140 [137, 144] | 139 [136, 142] | 0.065 | 3 | ||
| Potassium concentration, mmol/L | 4.0 [3.7, 4.6] | 4.0 [3.7, 4.5] | 4 0.0 [3.7, 4.5] | 4.1 [3.7, 4.7] | 0.590 | 3 | ||
| Magnesium concentration, mg/dL | 2.0 [1.8, 2.4] | 2.0 [1.8, 2.5] | 2.1 [1.9, 2.5] | 2.0 [1.8, 2.3] | 0.555 | 190 | ||
AF atrial fibrillation, ICU intensive care unit, MAP Mean arterial pressure, MV mechanical ventilation, RRT renal replacement therapy, SOFA Sequential Organ Failure Assessment.
Kruskal-Wallis tests for continuous variables, and chi-square tests or Fisher’s exact tests for categorical variables between the three groups.
Mean dose only for the patients administrated.
Patients with infections who have a SOFA score of 2 or higher at the initial AF onset were considered sepsis.
Patients with infections who have a SOFA score of 2 or higher, were treated with vasopressors, and have a lactate level of 2 mmol/l or higher at the initial AF onset were considered septic shock.
p < 0.05 vs. nighttime group after Bonferroni correction.
p < 0.05 vs. daytime group after Bonferroni correction.
Interventions and Outcomes: AF onset during evening and nighttime vs. daytime.
| Total | Nighttime | Daytime | Evening | Missing data | ||
|---|---|---|---|---|---|---|
| Variables | ||||||
| Antiarrhythmic drugs | 296 (70) | 93 (69) | 100 (71) | 103 (70) | 0.934 | 0 |
| Electrical cardioversion | 65 (15) | 26 (19) | 20 (14) | 19 (13) | 0.302 | 0 |
| Anticoagulants | 173 (41) | 61 (45) | 60 (43) | 52 (35) | 0.218 | 0 |
| SR after AF onset during ICU stay, n (%) | 380 (90) | 118 (87) | 128 (91) | 134 (91) | 0.525 | 0 |
| AF recurrence, n (%) | 89 (21) | 34 (25) | 21 (15) | 34 (23) | 0.083 | 0 |
| AF at ICU discharge, n (%) | 62 (17) | 19 (16) | 19 (16) | 24 (18) | 0.861 | 0 |
| ICU length of stay | 5.6 [2.6, 11.2] | 5.4 [2.5, 10.4] | 5.2 [2.8, 10.1] | 5.9 [2.7, 12.2] | 0.780 | 0 |
| Hospital length of stay | 26 [13, 49] | 31 [13, 55] | 25 [11, 51] | 23 [13, 46] | 0.355 | 0 |
| ICU mortality, n (%) | 54 (13) | 14 (10) | 25 (18) | 15 (10) | 0.096 | 0 |
| Hospital mortality, n (%) | 112 (26) | 29 (23) | 45 (32) | 38 (26) | 0.142 | 0 |
| Stroke after AF onset, n (%) | 19 (4.5) | 6 (4.4) | 5 (3.5) | 8 (5.4) | 0.767 | 0 |
AF atrial fibrillation, ICU intensive care unit, SR sinus rhythm.
Kruskal-Wallis tests for continuous variables, and chi-square tests or Fisher’s exact tests for categorical variables between the three groups.
Antiarrhythmic drugs includes any calcium-channel blockers, beta blocking agents, amiodarone, pilsicainide, magnesium sulfate, digoxin and others.
During AF from the initial AF onset.
Within seven days of the onset of AF or during ICU stay, whichever is shorter.
Length from the initial onset of AF to ICU discharge.
Length from the initial onset of AF to hospital discharge.
Multivariate logistic regression analysis for in-hospital mortality.
| Covariates | Adjusted OR (95% CI) | p value |
|---|---|---|
| AF onset time | ||
| ighttime | Reference | – |
| Daytime | 1.92 (1.07–3.44) | 0.030 |
| Evening | 1.10 (0.60–2.00) | 0.764 |
| Age, years | 1.01 (0.99–1.03) | 0.270 |
| APACHE II score, point | 1.06 (1.02–1.09) | 0.001 |
| Patient category | ||
| Scheduled surgery | Reference | – |
| Non-scheduled surgery | 1.07 (0.40–2.85) | 0.890 |
| Medical | 1.22 (0.48–3.12) | 0.675 |
| Mechanical ventilation at AF onset | 2.49 (1.38–4.48) | 0.002 |
| Renal replacement therapy at AF onset | 2.37 (1.39–4.03) | 0.002 |
| Vasopressors at AF onset | 0.93 (0.56–1.56) | 0.787 |
| Infection at AF onset | 0.98 (0.52–1.83) | 0.944 |
AF atrial fibrillation, APACHE II Acute Physiology and Chronic Health Evaluation II.
Fig. 1Circadian distribution of the AF onset and crude in-hospital mortality.
Fig. 2Circadian distribution of adjusted in-hospital mortality calculated with considering periodicity. The median is indicated by the black lines, and the 25th and 75th percentiles by the hinges, maximum value or 1.5 times of the interquartile range as the bars, and values beyond as points. The overlaid curve shows the predicted curve from the multivariate logistic regression model that took periodicity into account.